Dermatological Manifestations and Sebum Composition in Parkinson’s Disease

Meshi Paz; Peter Lio

doi:10.5826/dpc.1501a4921

Dermatological Manifestations and Sebum Composition in Parkinson’s Disease

Authors

Meshi Paz Tulane University School of Medicine
Peter Lio Feinberg School of Medicine, Northwestern University; Medical Dermatology Associates of Chicago https://orcid.org/0000-0001-7600-0152

Keywords:

Parkinson's Disease, dermatological mn, sebum composition, volatile organic compounds, Malassezia

Abstract

Introduction

Parkinson disease (PD) is a multifaceted neurodegenerative disorder known for its hallmark motor symptoms. However, nonmotor manifestations, specifically dermatological changes, precede motor symptoms and may thus serve as vital early indicators of PD.

Objectives

This article explores the skin-related changes associated with PD, focusing on alterations in sebum composition, microbial dysbiosis, and the potential for leveraging dermatological assessments as early, noninvasive diagnostic markers for PD.

Methods

A comprehensive literature review was conducted to investigate dermatological manifestations of PD, focusing on sebum changes in affected individuals. Research explored the clinical relevance of altered lipid profiles, volatile organic compound (VOC) contributions, and microbiome dysbiosis in those with PD.

Results

Individuals with PD exhibit excess sebum production characterized by altered lipid profiles, including elevated short-chain fatty acids (SCFAs) and disruptions in sphingolipid metabolism. The lipid-rich environment also promotes overgrowth of Malessezia yeast, contributing to varied dermatological symptoms in those with PD. VOCs identified in sebum have been linked to unique odors and serve as biomarkers for diagnostic potential. These findings support the potential for early PD diagnosis through dermatologic assessment and sebum analysis.

Conclusion

Dermatological manifestations in PD offer promising noninvasive biomarkers for early diagnosis. Future research should aim to further elucidate the mechanisms underlying sebum dysregulation in PD and validate the clinical relevance of these biomarkers in larger populations.

Author Biography

Peter Lio, Feinberg School of Medicine, Northwestern University; Medical Dermatology Associates of Chicago

Peter A. Lio, MD is a Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University Feinberg School of Medicine, a Fellow of the American Academy of Dermatology, and a Diplomate of the American Board of Dermatology. Dr. Lio focuses on conditions such as eczema, acne, and dermatomyositis, and he integrates alternative and complementary medicines into his practice. He founded the Chicago Integrative Eczema Center, emphasizing effective eczema treatment and related patient education. Dr. Lio is highly regarded for his significant contributions to dermatology education and research, with over 200 publications and three textbooks.

References

Shah P, Sagar PR, Alhumaidi N, Bollampally VC, Malik BH. Parkinson’s Disease and Its Dermatological Associations: Is Your Skin Whispering You a Diagnosis? Cureus. 2020;12(8):e9933. DOI:10.7759/cureus.9933

DeMaagd G, Philip A. Parkinson’s Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. P T Peer-Rev J Formul Manag. 2015;40(8):504-532.

Zafar S, Yaddanapudi SS. Parkinson Disease. In: StatPearls. StatPearls Publishing; 2024. Accessed May 24, 2024. http://www.ncbi.nlm.nih.gov/books/NBK470193/

Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435-450. DOI:10.1038/nrn.2017.62

Skorvanek M, Bhatia KP. The Skin and Parkinson’s Disease: Review of Clinical, Diagnostic, and Therapeutic Issues. Mov Disord Clin Pract. 2017;4(1):21-31. DOI:10.1002/mdc3.12425

Niemann N, Billnitzer A, Jankovic J. Parkinson’s disease and skin. Parkinsonism Relat Disord. 2021;82:61-76. DOI:10.1016/j.parkreldis.2020.11.017

Verma DK, Seo BA, Ghosh A, et al. Alpha-Synuclein Preformed Fibrils Induce Cellular Senescence in Parkinson’s Disease Models. Cells. 2021;10(7):1694. DOI:10.3390/cells10071694

Kamel M, Aleya S, Alsubih M, Aleya L. Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases. J Pers Med. 2024;14(2):217. DOI:10.3390/jpm14020217

Trivedi DK, Sinclair E, Xu Y, et al. Discovery of Volatile Biomarkers of Parkinson’s Disease from Sebum. ACS Cent Sci. 2019;5(4):599-606. DOI:10.1021/acscentsci.8b00879

Prakash KG, Bannur BM, Chavan MD, Saniya K, Sailesh KS, Rajagopalan A. Neuroanatomical changes in Parkinson’s disease in relation to cognition: An update. J Adv Pharm Technol Res. 2016;7(4):123-126. DOI:10.4103/2231-4040.191416

Kouli A, Torsney KM, Kuan WL. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB, Greenland JC, eds. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Codon Publications; 2018. Accessed May 24, 2024. http://www.ncbi.nlm.nih.gov/books/NBK536722/

Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson’s disease. Br J Pharmacol. 2007;150(8):963-976. DOI:10.1038/sj.bjp.0707167

Adam H, Gopinath SCB, Md Arshad MK, et al. An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment. 3 Biotech. 2023;13(5):142. DOI:10.1007/s13205-023-03553-8

Sonne J, Reddy V, Beato MR. Neuroanatomy, Substantia Nigra. In: StatPearls. StatPearls Publishing; 2024. Accessed May 24, 2024. http://www.ncbi.nlm.nih.gov/books/NBK536995/

Safai A, Prasad S, Chougule T, Saini J, Pal PK, Ingalhalikar M. Microstructural abnormalities of substantia nigra in Parkinson’s disease: A neuromelanin sensitive MRI atlas based study. Hum Brain Mapp. 2019;41(5):1323-1333. DOI:10.1002/hbm.24878

Gómez-Benito M, Granado N, García-Sanz P, Michel A, Dumoulin M, Moratalla R. Modeling Parkinson’s Disease With the Alpha-Synuclein Protein. Front Pharmacol. 2020;11:356. DOI:10.3389/fphar.2020.00356

Shahid W, Satyjeet F, Kumari R, et al. Dermatological Manifestations of Parkinson’s Disease: Clues for Diagnosis. Cureus. 12(10):e10836. DOI:10.7759/cureus.10836

Uehara Y, Ueno SI, Amano-Takeshige H, et al. Non-invasive diagnostic tool for Parkinson’s disease by sebum RNA profile with machine learning. Sci Rep. 2021;11(1):18550. DOI:10.1038/s41598-021-98423-9

Dinesh D, Lee JS, Gao X, Palacios N. Skin conditions in early Parkinson’s disease. Parkinsonism Relat Disord. 2021;84:40-46. DOI:10.1016/j.parkreldis.2021.01.018

Sinclair E, Trivedi DK, Sarkar D, et al. Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease. Nat Commun. 2021;12(1):1592. DOI:10.1038/s41467-021-21669-4

Picardo M, Ottaviani M, Camera E, Mastrofrancesco A. Sebaceous gland lipids. Dermatoendocrinol. 2009;1(2):68-71.

Mastrolonardo M, Diaferio A, Logroscino G. Seborrheic dermatitis, increased sebum excretion, and Parkinson’s disease: a survey of (im)possible links. Med Hypotheses. 2003;60(6):907-911. DOI:10.1016/S0306-9877(03)00094-X

Langan EA, Hinde E, Paus R. Prolactin as a candidate sebotrop(h)ic hormone? Exp Dermatol. 2018;27(7):729-736. DOI:10.1111/exd.13545

Han X, Bedarf J, Proske-Schmitz S, Schmitt I, Wüllner U. Increased diversity of Malassezia species on the skin of Parkinson’s disease patients. Front Aging Neurosci. 2023;15. DOI:10.3389/fnagi.2023.1268751

Dabby R, Djaldetti R, Shahmurov M, et al. Skin biopsy for assessment of autonomic denervation in Parkinson’s disease. J Neural Transm. 2006;113(9):1169-1176. DOI:10.1007/s00702-005-0431-0

Morgan J. Joy of super smeller: sebum clues for PD diagnostics. Lancet Neurol. 2016;15(2):138-139. DOI:10.1016/S1474-4422(15)00396-8

Géhin C, Tokarska J, Fowler SJ, Barran PE, Trivedi DK. No skin off your back: the sampling and extraction of sebum for metabolomics. Metabolomics. 2023;19(4):21. DOI:10.1007/s11306-023-01982-3

Briganti S, Truglio M, Angiolillo A, et al. Application of Sebum Lipidomics to Biomarkers Discovery in Neurodegenerative Diseases. Metabolites. 2021;11(12):819. DOI:10.3390/metabo11120819

Lobasso S, Tanzarella P, Vergara D, Maffia M, Cocco T, Corcelli A. Lipid profiling of parkin-mutant human skin fibroblasts. J Cell Physiol. 2017;232(12):3540-3551. DOI:10.1002/jcp.25815

Gonzalez M, Celis AM, Guevara-Suarez MI, Molina J, Carazzone C. Yeast Smell Like What They Eat: Analysis of Volatile Organic Compounds of Malassezia furfur in Growth Media Supplemented with Different Lipids. Molecules. 2019;24(3):419. DOI:10.3390/molecules24030419

Gu Y, Zhang J, Zhao X, et al. Olfactory dysfunction and its related molecular mechanisms in Parkinson’s disease. Neural Regen Res. 2023;19(3):583-590. DOI:10.4103/1673-5374.380875

Fullard ME, Morley JF, Duda JE. Olfactory Dysfunction as an Early Biomarker in Parkinson’s Disease. Neurosci Bull. 2017;33(5):515-525. DOI:10.1007/s12264-017-0170-x

Saunte DML, Gaitanis G, Hay RJ. Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment. Front Cell Infect Microbiol. 2020;10:112. DOI:10.3389/fcimb.2020.00112

Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657-673. DOI:10.1038/s41577-022-00684-6

Laurence M, Benito-León J, Calon F. Malassezia and Parkinson’s Disease. Front Neurol. 2019;10:758. DOI:10.3389/fneur.2019.00758

Arsic Arsenijevic VS, Milobratovic D, Barac AM, Vekic B, Marinkovic J, Kostic VS. A laboratory-based study on patients with Parkinson’s disease and seborrheic dermatitis: the presence and density of Malassezia yeasts, their different species and enzymes production. BMC Dermatol. 2014;14(1):5. DOI:10.1186/1471-5945-14-5

Rios-Navarro A, Gonzalez M, Carazzone C, Celis Ramírez AM. Why Do These Yeasts Smell So Good? Volatile Organic Compounds (VOCs) Produced by Malassezia Species in the Exponential and Stationary Growth Phases. Molecules. 2023;28(6):2620. DOI:10.3390/molecules28062620